medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2018, Number 1

<< Back Next >>

Alerg Asma Inmunol Pediatr 2018; 27 (1)

Kawasaki disease and toxic shock syndrome

Martínez PM, Gámez GLB, Moribe QI, Yamazaki NMA

Language: Spanish
References: 59
Page: 18-24
PDF size: 190.22 Kb.


ABSTRACT

Kawasaki disease is a vasculitic disorder in children sometimes associated with staphylococcal and streptococcal infections. Toxic shock syndrome is a multisystemic disease caused by the release of superantigens by Streptococcus and Staphylococcus. Patients with Kawasaki disease can also present with shock, and this particular subgroup of patients is very difficult to differenciate from patients with TSS.


REFERENCES

  1. Del Monte ME, González LR, García DM, Yamazaki NM, Huerta LJ. Síndrome de choque tóxico por enfermedad de Kawasaki; reporte de un caso en paciente de 10 meses de edad. Alergia Asma Inmunol Pediatr. 2016; 25: 30-33.

  2. Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-1 Staphylococci. Lancet. 1978; 2: 1116-1118.

  3. Teixeira OH, Pong AH, Vlad P. Amputatin gangrene in Kawasaki disease. Can Med Assoc J. 1982; 127: 132-134.

  4. Tomita S, Chung K, Mas M, Gidding S, Shulman ST. Peripheral gangrene associated with Kawasaki disease. Clin Infect Dis. 1992; 14: 121-126.

  5. Wiesenthal AM, Todd JK. Toxic shock syndrome in children aged 10 years or less. Pediatrics. 1984; 74: 112-117.

  6. Todd JK. Toxic shock syndrome. Clin Microb Rev. 1988; 1: 432-446.

  7. Curtis N. Toxic shock syndrome: under-recognised and under-treated? Arch Dis Child. 2014; 99: 1062-1064.

  8. Drage L. Life-threatening rashes: dermatologic signs of four infectious diseases. Mayo Clin Proc. 1999; 74: 68-72.

  9. Muro T, Maruyama Y, Onishi K, Saze M, Okada E, Matsuura H et al. Mimicking Kawasaki disease in burned children: report of four cases. Burns. 2009; 35: 594-549.

  10. Kato H, Koike S, Yamamoto M, Ito Y, Yano E. Coronary aneurysms in infants and young children with acute febrile mucocutaneous lymph node syndrome. J Pediatr. 1975; 86: 892-898.

  11. Dominguez SR, Friedman K, Seewald R, Anderson MS, Willis L, Glode MP. Kawasaki disease in a Pediatric Intensive Care Unit: A Case-control study. Pediatrics. 2008; 122 (4): 786-790.

  12. Kanegaye JT, Wilder MS, Molkara D, Frazer JR, Burns JC. Recognition of a Kawasaki disease shock syndrome. Pediatrics. 2009; 123; 783-789.

  13. Yim D, Ramsay J, Kothari D, Burgner D. Coronary artery dilatation in toxic shock-like syndrome: the Kawasaki disease shock syndrome. Pediatr Cardiol. 2010; 31: 1232-1235.

  14. Prieto MB, Bartolomé SM, Sebastián MM, López-Herce Cid J. Shock as initial presentation of Kawasaki disease. An Pediatr (Barc). 2009; 71: 372-374.

  15. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974; 54: 271e6.

  16. Saltigeral SP, Garrido GL, Camacho RL, Soto AK, Yamazaki NM. Enfermedad de Kawasaki. ¿La fi ebre debe ser un criterio obligatorio? Rev Alerg Mex. 2008; 55: 176-179.

  17. Gámez-González LB, Rivera-Rodríguez L, García-Pavon S, Rivas-Larrauri F, Yamazaki-Nakashimada M. Kawasaki disease without fever: a mild disease? Ann Paediatr Rheum. 2015; 4: 70-75.

  18. Manders SM, Heymann WR, Atillasoy E, Kleeman J, Schlievert PM. Recurrent toxin-mediated perineal erythema. Arch Dermatol. 1996; 132: 5.

  19. Akiyama T. Yashiro K. Probable role of Streptococcus pyogenes in Kawasaki disease. Eur J Pediatr. 1993; 152: 82-92.

  20. Anderson D, Warner G, Barlow E. Kawasaki disease associated with streptococcal infection within a family. J Paediatr Child Health. 1995; 31: 355-357.

  21. Barton M, Melbourne R, Morais P, Christie C. Kawasaki syndrome associated with group A streptococcal and Epstein-Barr virus co-infections. Ann Trop Paediatr. 2002; 22: 257-260.

  22. Cox F, Foshee W, Miller J Jr, Moore S. Simultaneous Kawasaki disease and group A streptococcal pharyngitis. Clin Pediatr (Phila). 1993; 32: 48-50.

  23. Rider LG, Mendelman PM, French J, Sherry DD. Group A streptococcal infection and Kawasaki syndrome. Lancet. 1991; 337: 1100-1101.

  24. Melamed I, Diamant S, Fattal A, Spirer Z. Kawasaki disease with serological evidence of streptococcal infection. Infection. 1986; 14: 91-92.

  25. Masuda M, Nakanishi K, Yoshizawa N, Iijima K, Yoshikawa N. Group A streptococcal antigen in the glomeruli of children with Henoch-Schönlein nephritis. Am J Kidney Dis. 2003; 41: 366-370.

  26. Benseler S, McCrindle B, Silverman E, Tyrrell P, Wong J, Yeung RS. Infections and Kawasaki disease: implications for coronary artery outcome. Pediatrics. 2005; 116: e760-e766.

  27. Anderson DG, Warner G, Barlow E. Kawasaki disease associated with streptococcal infection within a family. J Paediatr Child Health. 1995; 31: 355-357.

  28. Leahy TR, Cohen E, Allen UD. Incomplete Kawasaki disease associated with complicated Streptococcus pyogenes pneumonia: a case report. Can J Infect Dis Med Microbiol. 2012; 23: 137-139.

  29. Hall M, Hoyt L, Ferrieri P, Schlievert PM, Jenson HB. Kawasaki syndrome-like illness associated with infection caused by enterotoxin B-secreting Staphylococcus aureus. Clin Infect Dis. 1999; 29: 586-589.

  30. Chan L, Chinnock B. Clinicopathological conference: multisystem failure in a child. Acad Emerg Med. 2000; 7 (2): 169-173.

  31. Bosland A, Arlaud K, Rousset-Rouvière C, Fouilloux V, Paut O, Dubus JC, et al. Streptococcal toxic shock syndrome or Kawasaki disease? Two case studies of children with group A streptococcal pneumonia empyema. Arch Pediatr. 2011; 12: 1310-1314.

  32. Hoare S, Abinun M, Cant AJ. Overlap between Kawasaki disease and group A streptococcal infection. Pediatr Infect Dis J. 1997; 16: 633-634.

  33. Odièvre MH, Valdès L, Billiard M, Weill C, Michot AS, Olivier C. Staphylococcal toxic syndrome, atypical presentation of Kawasaki syndrome or staphylococcal skin syndrome? Arch Pediatr. 2002; 9: 155-158.

  34. Saha A, Khalili S, Kapoor K, Gupta A, Dubey NK. Kawasaki shock syndrome presenting as toxic shock syndrome. Int J Rheum Dis. 2013; 4: 480-482.

  35. Davies HD, Kirk V, Jadavji T, Kotzin BL. Simultaneous presentation of Kawasaki disease and toxic shock syndrome in an adolescent male. Pediatr Infect Dis J. 1996;15: 1136- 1138.

  36. Rivera JM, Garcia-Bragado F, Jimenez P, Rodriguez J, Lozano-Gutierrez F, Grilo A. Síndrome de choque tóxico frente a síndrome de Kawasaki del adulto. Difi cultades diagnósticas. Med Clin. 1992; 98: 458-460.

  37. Gamillscheg A, Zobel G, Karpf EF, Dacar D, Beitzke A, Stein JI et al. Atypical presentation of Kawasaki disease in an infant. Pediatr Cardiol. 1993; 14: 223-226.

  38. Michels TC. Mucocutaneous lymph node syndrome in adults. Differentiation from toxic shock syndrome. Am J Med. 1986; 80: 724-728.

  39. Milgrom H, Palmer EL, Slovin SF, Morens DM, Freedman SD, Vaughan JH. Kawasaki disease in healthy young adult. Ann Intern Med. 1980; 92: 467-470.

  40. Milgrom H, Palmer EL, Slovin SF, Morens DM, Freedman SD, Vaughan JH. Toxic shock syndrome or Kawasaki disease. Ann Intern Med. 1981; 94: 138.

  41. Butler DF, Hough DR, Friedman SJ, Davis HE. Adult Kawasaki syndrome. Arch Dermatol. 1987; 123: 1356-1361.

  42. Zulian F, Falcini F, Zancan L, Martini G, Secchieri S, Luzzatto C, Zacchello F. Acute surgical abdomen as presenting manifestation of Kawasaki disease. J Pediatr. 2003; 142: 731-735.

  43. Gámez-González LB, Murata C, Muñoz-Ramírez M, Yamazaki-Nakashimada M. Clinical manifestations associated with Kawasaki disease shock syndrome in Mexican children. Eur J Pediatr. 2013; 172: 337-342.

  44. Matsubara K, Fukaya T. The role of superantigens of group A streptococcus and Staphylococcus aureus in Kawasaki disease. Curr Opin Infect Dis. 2007; 20: 298-303.

  45. Leung DY, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet. 1993; 342: 1385-1388.

  46. Abe J, Kotzin BL, Jujo K, Melish ME, Glode MP, Kohsaka T, Leung DY. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci USA. 1992; 89: 4066-4070.

  47. Nomura Y, Yoshinaga M, Masuda K, Takei S, Miyata K. Maternal antibody against toxic shock syndrome toxin-1 may protect infants younger than 6 months of age from developing Kawasaki syndrome. J Infect Dis. 2002; 185: 1677-1680.

  48. Lin YJ, Cheng MC, Lo MH, Chien SJ. Early differentiation of Kawasaki disease shock syndrome and toxic shock syndrome in a Pediatric Intensive Care Unit. Pediatr Infect Dis J. 2015; 34: 1163-1167.

  49. Lin KH, Chang SS, Yu CW, Lin SC, Liu SC, Chao HY et al. Usefulness of natriuretic peptide for the diagnosis of Kawasaki disease: a systematic review and meta-analysis. BMJ Open. 2015; 5 (4): e006703.

  50. Papanikolaou J, Makris D, Mpaka M, Palli E, Zygoulis P, Zakynthinos E. New insights into the mechanisms involved in B-type natriuretic peptide elevation and its prognostic value in septic patients. Crit Care. 2014; 18 (3): R94.

  51. Wiesenthal AM, Ressman M, Caston SA, Todd JK. Toxic shock syndrome. Clinical exclusion of other síndromes by strict screening defi nition. Am J Epidemiol. 1985; 122: 847-856.

  52. Gama C, Breeden K, Miller R. Myositis in Kawasaki disease. Pediatr Neurol. 1990; 6 (2): 135-136.

  53. Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A. Clinical effi cacy of polyspecifi c intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 2014; 59 (6): 851-7. doi: 10.1093/cid/ciu449. Epub 2014 Jun 13.

  54. Sriskandan S, McKee A, Hall L, Cohen J. Comparative effects of clindamycin and ampicillin on superantigenic activity of Streptococcus pyogenes. J Antimicrob Chemother. 1997; 40 (2): 275-277.

  55. Herbert S, Barry P, Novick RP. Subinhibitory clindamycin differentially inhibits transcription of exoprotein genes in Staphylococcus aureus. Infect Immun. 2001; 69 (5): 2996-3003.

  56. Son MB, Newburger JW. Management of Kawasaki disease: corticosteroids revisited. Lancet. 2012; 379: 1571-1572.

  57. Krakauer T, Buckley M. Dexamethasone attenuates staphylococcal enterotoxin B-induced hypothermic response and protects mice from superantigen-induced toxic shock. Antimicrob Agents Chemother. 2006; 50: 391-395.

  58. Thabet F, Bafaqih H, Al-Mohaimeed S, Al-Hilali M, Al-Sewairi W, Chehab M. Shock: an unusual presentation of Kawasaki disease. Eur J Pediatr. 2011; 170: 941-943.

  59. Chen PS, Chi H, Huang FY, Peng CC, Chen MR, Chiu NC. Clinical manifestations of Kawasaki disease shock syndrome: a case-control study. J Microbiol Immunol Infect. 2015; 48: 43-50.




2020     |     www.medigraphic.com